Wörner, Tobias P.
Bennett, Antonette
Habka, Sana
Snijder, Joost
Friese, Olga
Powers, Thomas
Agbandje-McKenna, Mavis
Heck, Albert J. R. http://orcid.org/0000-0002-2405-4404
Funding for this research was provided by:
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (SPI.2017.028, ICI 024.002.009, TTW project 15575)
U.S. Department of Health & Human Services | NIH | NIH Office of the Director (GM109524)
NSF | Directorate for Mathematical & Physical Sciences | Division of Mathematical Sciences (1563234)
Article History
Received: 24 November 2020
Accepted: 4 February 2021
First Online: 12 March 2021
Competing interests
: O.F. and T.P. are employees of Pfizer WRDM, St Louis, MO, a company with interest in employing AAV vectors for gene delivery purposes. M.A.-M. is co-founder of StrideBio, Inc., with an interest in developing AAV technology for gene delivery purposes. M.A.-M. is a member of the ATGC and Voyager SAB, and consultants for StrideBio, Intima Bioscience, being biopharma companies with interest in developing AAV for gene delivery purposes. The remaining authors declare no competing interests.